Takeda Looks Up As It ‘Hits Bottom’
This article was originally published in PharmAsia News
Executive Summary
Following the massive financial hit of the recent Actos settlement, Takeda appears set to return to profitable growth this fiscal year after a 12-month period during which its new CEO says the Japanese firm "hit bottom."